For research use only. Not for use in humans.

Mavrilimumab (Anti-CSF2Ra/GM-CSFRa/CD116)

Synonyms: CAM 3001 Cat.No.A2532 Purity:99%

Mavrilimumab (Anti-CSF2Ra/GM-CSFRa/CD116) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. MW: 145.5 KD.

1 Citation

17 Nobel Prize winners
have used Selleck products

Shimon Sakaguchi

Nature Communications 2025;16, Article number:1325

David Baker

Dev Cell 2023;58(20):2163-2180.e9.

Michael Houghton

Cell Chem Biol 2020;27(7):780-792.e5

David Julius

Cell 2017;185-198.e16

Charles M. Rice

Cell 2018;172(3):423-438.e25

Quality Control

Batch: A253201 Purity: 99% Protein concentration: 6.39mg/ml Endotoxin Level: ＜1EU/mg

Cited in Nature Medicine for its top-tier quality
COA
SDS
Datasheet

Specificity

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Mavrilimumab (Anti-CSF2Ra/GM-CSFRa/CD116) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. MW: 145.5 KD.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1085337-57-0
Molecular Weight	145.5 kDa
Isotype	Human IgG4SP
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Sellecks selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.